Ocular Therapeutix, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company's bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye. Its lead product candidates are DEXTENZA (dexamethasone insert), for the treatment of post-surgical ocular inflammation and pain, allergic conjunctivitis and dry eye disease, and OTX-TP, for the treatment of glaucoma and ocular hypertension, which are extended-delivery, drug-eluting inserts that are placed into the canaliculus through a natural opening called the punctum located in the inner portion of the eyelid near the nose. It also has an intravitreal hydrogel depot, which is in preclinical development for the treatment of diseases and conditions of the back of the eye, including wet age-related macular degeneration (wet AMD).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Equipment, Supplies & Distribution - NEC
- Sub-Industry: N/A
- Symbol: NASDAQ:OCUL
- CUSIP: N/A
- Web: www.ocutx.com
Capitalization:- Market Cap: $195.07 million
- Outstanding Shares: 29,028,000
Average Prices:- 50 Day Moving Avg: $9.41
- 200 Day Moving Avg: $8.86
- 52 Week Range: $4.04 - $11.91
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -3.31
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $1.9 million
- Price / Sales: 102.67
- Book Value: $2.21 per share
- Price / Book: 3.04
Profitability:- EBIDTA: ($47,550,000.00)
- Net Margins: -2,620.06%
- Return on Equity: -80.26%
- Return on Assets: -59.06%
Debt:- Debt-to-Equity Ratio: 0.26%
- Current Ratio: 9.63%
- Quick Ratio: 9.62%
Misc:- Average Volume: 1.45 million shs.
- Beta: 1.73
- Short Ratio: 5.55
Frequently Asked Questions for Ocular Therapeutix (NASDAQ:OCUL)
What is Ocular Therapeutix's stock symbol?
Ocular Therapeutix trades on the NASDAQ under the ticker symbol "OCUL."
How were Ocular Therapeutix's earnings last quarter?
Ocular Therapeutix, Inc. (NASDAQ:OCUL) released its quarterly earnings data on Friday, May, 5th. The company reported ($0.58) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by $0.10. The company had revenue of $0.48 million for the quarter, compared to analysts' expectations of $0.51 million. Ocular Therapeutix had a negative net margin of 2,620.06% and a negative return on equity of 80.26%. During the same period last year, the company posted ($0.35) EPS. View Ocular Therapeutix's Earnings History.
Where is Ocular Therapeutix's stock going? Where will Ocular Therapeutix's stock price be in 2017?
6 brokerages have issued 1-year price objectives for Ocular Therapeutix's stock. Their forecasts range from $5.84 to $60.00. On average, they expect Ocular Therapeutix's share price to reach $23.31 in the next year. View Analyst Ratings for Ocular Therapeutix.
What are analysts saying about Ocular Therapeutix stock?
Here are some recent quotes from research analysts about Ocular Therapeutix stock:
- 1. According to Zacks Investment Research, "Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company develops and markets eye care products. Ocular Therapeutix, Inc. is headquartered in Bedford, Massachusetts. " (5/23/2017)
- 2. Cantor Fitzgerald analysts commented, "We are initiating on Ocular Therapeutix with an Overweight rating and $35 Price target. We believe Ocular's portfolio of sustained release therapies have the potential to treat an array of ophthalmic conditions with significant unmet need. In focus, we view the upcoming FDA decision this year for lead developmental candidate DEXTENZA' in post-surgical ocular pain as a meaningful catalyst for the shares, and estimate that DEXTENZA could reach annual sales of $600 million at peak market penetration in 2023, with further growth to $900 million by 2030 for this indication alone in the U.S." (2/9/2017)
Who are some of Ocular Therapeutix's key competitors?
Some companies that are related to Ocular Therapeutix include Syneron Medical (ELOS), Sientra (SIEN), Transenterix (TRXC), Transenterix (TRXC), T2 Biosystems (TTOO), Bioquell plc (BQE), Cytori Therapeutics (CYTX), Tandem Diabetes Care (TNDM), Capnia (SLNO), Surgical Innovations Group Plc (SUN), Alliqua BioMedical (ALQA), Lombard Medical (EVAR), InspireMD (NSPR), NeuroMetrix (NURO), CareFusion (CFN), Covidien Ltd (COV), CRH Medical Corp (CRHM) and Great Basin Scientific (GBSN).
Who are Ocular Therapeutix's key executives?
Ocular Therapeutix's management team includes the folowing people:
- Amarpreet Sawhney Ph.D., Executive Chairman of the Board
- Antony Charles Mattessich, President, Chief Executive Officer, Director
- James Fortune, Interim Principal Financial Officer, Chief Operating Officer, Interim Princiapl Accounting Officer
- George V. Migausky, Interim Chief Financial Officer
- Eric P. Ankerud, Executive Vice President, Regulatory, Quality and Compliance
- Andy Hurley, Chief Commercial Officer
- Jonathan Talamo M.D., Chief Medical Officer
- Jaswinder S. Chadha, Director
- W. James O'Shea, Director
- Jeffrey S. Heier M.D., Independent Director
Who owns Ocular Therapeutix stock?
Ocular Therapeutix's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Nottingham Advisors Inc. (0.50%), NEXT Financial Group Inc (0.14%) and Berson & Corrado Investment Advisors LLC (0.09%). Company insiders that own Ocular Therapeutix stock include Amarpreet Sawhney and James Fortune. View Institutional Ownership Trends for Ocular Therapeutix.
Who sold Ocular Therapeutix stock? Who is selling Ocular Therapeutix stock?
How do I buy Ocular Therapeutix stock?
Shares of Ocular Therapeutix can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ocular Therapeutix's stock price today?
One share of Ocular Therapeutix stock can currently be purchased for approximately $6.72.
MarketBeat Community Rating for Ocular Therapeutix (NASDAQ OCUL)MarketBeat's community ratings are surveys of what our community members think about Ocular Therapeutix and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Ocular Therapeutix (NASDAQ:OCUL) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Hold Ratings, 4 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.67) |
| Consensus Price Target: | $23.31 (246.83% upside) |
Analysts' Ratings History for Ocular Therapeutix (NASDAQ:OCUL)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/17/2017 | BTIG Research | Reiterated Rating | Neutral | | Low |  |
| 7/14/2017 | Morgan Stanley | Reiterated Rating | Equal Weight | $16.00 -> $8.00 | Low | |
| 7/12/2017 | Cantor Fitzgerald | Lower Price Target | Overweight -> Overweight | $35.00 -> $21.00 | High | |
| 3/13/2017 | Cowen and Company | Reiterated Rating | Outperform | $60.00 | Medium | |
| 11/15/2016 | Royal Bank Of Canada | Reiterated Rating | Outperform | $30.00 -> $32.00 | N/A | |
| 8/11/2016 | JMP Securities | Initiated Coverage | Outperform | $21.00 -> $5.84 | N/A | |
| 8/5/2015 | Nomura | Initiated Coverage | Buy | $46.00 | N/A | |
(Data available from 7/22/2015 forward)
Earnings History for Ocular Therapeutix (NASDAQ:OCUL)Earnings History by Quarter for Ocular Therapeutix (NASDAQ OCUL)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/5/2017 | Q1 2017 | ($0.48) | ($0.58) | $0.51 million | $0.48 million | View | N/A | |
| 3/10/2017 | Q4 2016 | ($0.45) | ($0.52) | $0.48 million | $0.51 million | View | N/A | |
| 11/9/2016 | Q316 | ($0.50) | ($0.39) | $0.47 million | $0.48 million | View | Listen | |
| 8/9/2016 | Q216 | ($0.49) | ($0.46) | $0.55 million | $0.44 million | View | Listen | |
| 5/10/2016 | Q116 | ($0.43) | ($0.44) | | $458.00 million | View | Listen | |
| 3/10/2016 | Q415 | ($0.47) | ($0.43) | | $0.44 million | View | Listen | |
| 11/10/2015 | Q315 | ($0.38) | ($0.47) | | $0.43 million | View | Listen | |
| 8/10/2015 | Q215 | ($0.33) | ($0.45) | | $0.46 million | View | Listen | |
| 5/15/2015 | Q115 | ($0.39) | ($0.35) | $0.30 million | $0.43 million | View | Listen | |
| 3/10/2015 | Q4 | ($0.38) | ($0.37) | $0.20 million | $0.51 million | View | Listen | |
| 11/12/2014 | Q3 14 | ($0.55) | ($0.48) | $0.10 million | $0.14 million | View | Listen | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Ocular Therapeutix (NASDAQ:OCUL)Current Year EPS Consensus Estimate: $-2.22 EPS
Next Year EPS Consensus Estimate: $-2.03 EPS
Dividend History for Ocular Therapeutix (NASDAQ:OCUL)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Ocular Therapeutix (NASDAQ:OCUL)Insider Ownership Percentage: 26.10%
Institutional Ownership Percentage: 65.25%
Insider Trades by Quarter for Ocular Therapeutix (NASDAQ:OCUL)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 12/15/2016 | Amarpreet Sawhney | Insider | Buy | 45,300 | $7.85 | $355,605.00 | |
| 6/9/2016 | Amarpreet Sawhney | CEO | Buy | 10,000 | $6.70 | $67,000.00 | |
| 11/17/2015 | Amarpreet Sawhney | CEO | Buy | 10,000 | $8.25 | $82,500.00 | |
| 9/15/2015 | James Fortune | COO | Sell | 9,470 | $17.16 | $162,505.20 | |
| 9/14/2015 | Amarpreet Sawhney | CEO | Buy | 15,000 | $16.50 | $247,500.00 | |
| 6/15/2015 | Charles M Warden | Director | Sell | 320,000 | $22.00 | $7,040,000.00 | |
| 6/10/2015 | Charles M Warden | Director | Sell | 427,000 | $22.00 | $9,394,000.00 | |
| 6/10/2015 | Svlsf Iv, Llc | Major Shareholder | Sell | 1,119,000 | $22.00 | $24,618,000.00 | |
| 7/30/2014 | Amarpreet Sawhney | CEO | Buy | 76,922 | $13.00 | $999,986.00 | |
| 7/30/2014 | Svlsf Iv, Llc | Major Shareholder | Buy | 715,380 | $13.00 | $9,299,940.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Ocular Therapeutix (NASDAQ:OCUL)
Latest Headlines for Ocular Therapeutix (NASDAQ:OCUL)
| Source: |
|
| Date | Headline |
|---|
 | Investor Alert: Kaplan Fox Announces Investigation Of Ocular Therapeutix, Inc. - PR Newswire (press release)
www.prnewswire.com - July 21 at 5:17 AM |
 | INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Ocular Therapeutix, Inc. of a Class Action Lawsuit ... - Business Wire (press release)
www.businesswire.com - July 21 at 5:17 AM |
 | OCUL SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Ocular Therapeutix, Inc. and a Lead Plaintiff Deadline of September 5, 2017
finance.yahoo.com - July 21 at 5:17 AM |
| SHAREHOLDER ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - July 21 at 5:17 AM |
 | Analysts Expect Ocular Therapeutix, Inc. (NASDAQ:OCUL) to Announce -$0.64 Earnings Per Share
www.americanbankingnews.com - July 20 at 9:15 AM |
| SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Ocular Therapeutix, Inc. (OCUL) & Lead Plaintiff Deadline: September 5, 2017
finance.yahoo.com - July 20 at 5:10 AM |
| Investor Alert: Kaplan Fox Announces Investigation Of Ocular Therapeutix, Inc.
finance.yahoo.com - July 20 at 5:10 AM |
| EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - July 20 at 5:10 AM |
| INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Ocular Therapeutix, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 5, 2017
finance.yahoo.com - July 20 at 5:10 AM |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Ocular Therapeutix, Inc. of a Class Action ... - Business Wire (press release)
www.businesswire.com - July 19 at 5:44 AM |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Ocular Therapeutix, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 5, 2017
finance.yahoo.com - July 19 at 12:43 AM |
| IMPORTANT EQUITY ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - July 19 at 12:43 AM |
| The Klein Law Firm Reminds Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Ocular Therapeutix, Inc.
finance.yahoo.com - July 18 at 6:53 AM |
| SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - July 18 at 6:53 AM |
| Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stock Rating Reaffirmed by BTIG Research
www.americanbankingnews.com - July 17 at 11:05 AM |
| FY2017 EPS Estimates for Ocular Therapeutix, Inc. Lifted by Cantor Fitzgerald (OCUL)
www.americanbankingnews.com - July 17 at 8:58 AM |
| EQUITY ALERT UPDATE: Rosen Law Firm Expands First Filed Securities Class Action against Ocular Therapeutix, Inc ... - Business Wire (press release)
www.businesswire.com - July 16 at 11:50 PM |
| The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws ... - Business Wire (press release)
www.businesswire.com - July 16 at 1:46 PM |
| Robbins Arroyo LLP: Ocular Therapeutix, Inc. (OCUL) Misled Shareholders According to a Recently Filed Class Action
www.businesswire.com - July 15 at 7:09 AM |
| EQUITY ALERT UPDATE: Rosen Law Firm Expands First Filed Securities Class Action against Ocular Therapeutix, Inc. to Include Investors Who Purchased up to July 11, 2017
finance.yahoo.com - July 15 at 7:09 AM |
| The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Ocular Therapeutix, Inc.
finance.yahoo.com - July 15 at 7:09 AM |
| SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ocular Therapeutix, Inc. of Class Action Lawsuit and Upcoming Deadline - OCUL
finance.yahoo.com - July 15 at 7:09 AM |
| Ocular Therapeutix, Inc. (OCUL) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - July 14 at 11:20 AM |
| Ocular Therapeutix, Inc. (OCUL) Rating Reiterated by Morgan Stanley
www.americanbankingnews.com - July 14 at 10:46 AM |
| RM LAW Announces Class Action Lawsuit Against Ocular Therapeutix, Inc. - PR Newswire (press release)
www.prnewswire.com - July 14 at 7:05 AM |
| OCUL INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Ocular Therapeutix, Inc.
finance.yahoo.com - July 14 at 7:05 AM |
| IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - July 14 at 7:05 AM |
| Ocular Therapeutix faces fraud allegations as FDA rejects eye drug
finance.yahoo.com - July 14 at 7:05 AM |
| Safirstein Metcalf LLP Announces that A Class Action Has Been Filed Against Ocular Therapeutix, Inc. – OCUL
finance.yahoo.com - July 14 at 7:05 AM |
| INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - July 14 at 7:05 AM |
 | Ocular Therapeutix Gets CRL For DEXTENZA
www.rttnews.com - July 13 at 7:37 AM |
 | BRIEF-Ocular Therapeutix receives complete response letter from FDA for Dextenza NDA
www.businessinsider.com - July 13 at 7:37 AM |
 | Why Ocular Therapeutix Shares Are Getting Crushed
247wallst.com - July 13 at 7:37 AM |
 | Ocular Therapeutix Falls 30% After Major Setback In Dextenza
www.benzinga.com - July 13 at 7:36 AM |
| The Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Ocular Therapeutix, Inc. Investors and Encourages Investors to Contact the Firm
finance.yahoo.com - July 13 at 7:36 AM |
| OCUL SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Ocular Therapeutix, Inc.
finance.yahoo.com - July 13 at 7:36 AM |
| IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - July 13 at 7:36 AM |
| OCULAR THERAPEUTIX ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Ocular Therapeutix, Inc. To Contact The Firm
finance.yahoo.com - July 13 at 7:36 AM |
| IMPORTANT OCULAR THERAPEUTIX, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the District of New Jersey against Ocular Therapeutix, Inc.
finance.yahoo.com - July 13 at 7:36 AM |
| RM LAW Announces Class Action Lawsuit Against Ocular Therapeutix, Inc.
finance.yahoo.com - July 13 at 7:36 AM |
| EQUITY ALERT: Goldberg Law PC Announces the Filing of a Securities Class Action Lawsuit against Ocular Therapeutix, Inc.
finance.yahoo.com - July 13 at 7:36 AM |
| SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Ocular Therapeutix, Inc. and Certain Officers – OCUL
feeds.benzinga.com - July 12 at 7:46 PM |
| IMPORTANT EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Encourages Investors with Losses to Contact the Firm
feeds.benzinga.com - July 12 at 7:46 PM |
| Cantor Fitzgerald Trims Ocular Therapeutix, Inc. (NASDAQ:OCUL) Target Price to $21.00
www.americanbankingnews.com - July 12 at 12:44 PM |
| OCULAR THERAPEUTIX INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses ... - Business Wire (press release)
www.businesswire.com - July 12 at 6:36 AM |
 | BRIEF-Ocular Therapeutix submits amendment to potentially extend review for Dextenza NDA - Reuters
www.reuters.com - July 12 at 6:36 AM |
| SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Ocular ... - PR Newswire (press release)
www.prnewswire.com - July 12 at 6:36 AM |
| Block & Leviton Announces Class Action Lawsuit Against Ocular Therapeutix, Inc. (OCUL) And Encourages ... - PR Newswire (press release)
www.prnewswire.com - July 12 at 6:36 AM |
 | Ocular Therapeutix shares plummet after FDA pushes back on eye-drug approval - MarketWatch
www.marketwatch.com - July 12 at 6:36 AM |
 | Here's Why Ocular Therapeutix Inc Rose 25.6% Today - Motley Fool
www.fool.com - July 12 at 6:36 AM |
Ocular Therapeutix (OCUL) Chart for Saturday, July, 22, 2017
